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Abstract 
Efficient administration of poorly water soluble drugs represents a leading 
challenge in pulmonary medicine. This route of administration has been used for 
steroidal treatments for some time, but with room for advancement. New 
inhalable medicines require a more reliable and effective dosing regimen due to 
narrow therapeutic indices, and specific and enhanced deposition in the lungs is 
also desired. This thesis investigates a general method for producing micron sized 
dry powders for a general class of drugs, poorly water soluble small molecule 
drugs, for their use in pulmonary drug delivery. Formulation methods already 
exist for inhalable aerosols, but the resulting powders often show limited 
deposition efficiency in the deep lung. In this body of work, an alternative 
formulation strategy is provided for inhalable dry powders using nanoparticle 
agglomeration that results in a potentially more efficient line of therapy. The 
model drug used in this study was nifedipine, a well known calcium channel 
blocker used to treat various symptoms of hypertension. The results indicated that 
nanoparticle agglomeration is a viable means of creating dry powders with 
suitable characteristics for pulmonary drug delivery as an alternative to more 
expensive and less controllable formulation strategies. 
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Drug delivery is a rapidly growing field of research, and pulmonary drug 
delivery has seen numerous advances in recent years.1 As technologies become 
more adept at characterizing and manipulating microscopic and submicron 
materials, the ability to reliably produce entities on this scale continually 
improves. Drug delivery science has rapidly sought to put these improvements to 
application.2 Traditionally, nanoparticles and microparticles have represented the 
primary delivery vehicles for a host of drugs, where ‘nanoparticles’ denotes 
pieces of material with diameters between 1 and 1000 nm and ‘microparticles’ 
have diameters between 1 and 1000 µm. The “ideal” drug nanoparticle may be 
equipped with a milieu of functions; everything it needs to carry out any number 
of activities on the cellular level.3 A perfect nanoscale drug carrier may be many 
years away, but rudimentary nano- and microparticles still yield enormous 
benefits compared to traditional dosage forms.4 In the past few decades, it has 
become clear that particulates are a benchmark design strategy for drug delivery 
scientists, representing a fundamental challenge for those interested in pulmonary 
delivery.5  
Two general classes of particulates may be studied in pulmonary delivery: 
nanoparticles and microparticles. Microparticles are an effective vehicle for 
pulmonary drug delivery.6 If they are manufactured in the correct size range, 
anywhere between 1 and 5 µm, they can reliably deposit into the terminal 
bronchioles and alveolar regions of the pulmonary bed.7 Also, if their densities are 
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sufficiently low, anything less than ~0.4 g/cm3, then particles greater than 5 µm 
may be used.6 This prepared study focused on the storage and aerosolization of 
microparticle dry powders and determine their performance in the pulmonary 
airways. These powders are delivered to the lungs via dry powder inhalers (DPIs), 
as opposed to nebulized liquid droplets or pressurized suspensions of drugs that 
are stored in metered dose inhalers (MDIs).8-10 DPIs characteristically rely on the 
force provided by a patient’s inhalation to disperse and transport the particles into 
the lungs.9 The following figure represents the steps involved in delivering 
powders to the lungs with a DPI.  
 
 
 
 
Inhaler
Powder to be dispersed
Inhalation air
Mouthpiece
Inhaled powder
particles
Figure 1.1 Diagram of a generalized dry powder inhaler in action. Adapted from 
Finlay, 2001.  
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The method of aerosolization is in contrast to MDIs, which almost always 
contain some sort of propellant which pressurizes the contents of their drug 
containing vessel, and this pressure provides the force necessary to push the 
nebulized liquid droplets into the patient’s airways.9 The DPI’s mode of dispersal 
can cause insufficient aerosolization, especially if a patient exhibits weak 
inspiration as is often the case with diseased lung tissue.11 DPIs require no 
coordination with a forced dose, include no environmentally harmful propellants, 
and are often cheaper to manufacture. 
Dry particles may deposit along the airways via three primary mechanisms: 
Inertial impaction, sedimentation, and diffusion.9,12-15 These events, though 
mostly noncompetitive, may all occur for a single dose of particles. They are 
represented in the figure below. 
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Airflow
Inertial Impaction
Sedimentation
Diffusion
 
Figure 1.2 Diagram of the three non competing drug transport events that occur 
during pulmonary drug delivery. Adapted from Hillary, et al., 2001.  
 
Sedimentation refers to the gravitationally guided deposition of particles along 
the pulmonary airways. In most models, particles enter the airways with a velocity 
field that is parallel to the axial direction, and subsequently fall vertically upon the 
walls of the cylinder.13 This mechanism dominates in the lower airways, and so 
may be exploited in deep lung delivery.9 Enhanced deposition by this method is 
heavily dependent on time and this is one reason patients are asked to hold their 
breath upon inhalation.9,14,15 
Inertial impaction refers to the deposition of particles as they stray from the 
angled air flow lines that pass through the many lung bifurcations. The particles 
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are unable to follow the velocity field because of their inherent inertia and their 
momentum straight forward is greater than the pull of the airflow around the 
curved bronchial tubes. This is commonly found to be the primary means of 
deposition for particles greater than 1 µm.9 Porous particles, however, have 
recently been investigated for their ability to avoid premature deposition due to 
impaction.15 Aerodynamic diameter is a very influential parameter for controlling 
inertial impaction. A geometrically large particle with a small aerodynamic 
diameter essentially means that the particle moves as if it were a much smaller 
particle of unit density. A smaller particle carries with it a smaller amount of 
inertia and so this translates to a lower susceptibility to inertial impaction. The 
governing equation is shown below. 
ge
water
particle
ae dd ×⎟⎟⎠
⎞
⎜⎜⎝
⎛
×=
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ρ
      (1) 
 The variables  and particleρ waterρ  are the densities of the particle material and 
water, respectively, dge is the geometric particle diameter, and γ is a shape factor 
(1 for a sphere and almost always increasing for irregular shapes).16  
Diffusion is the third and least probable mechanism for the deposition of 
particles > 1 µm, and is effectively negligible for particles > 3.5 µm.9,13 This 
mechanism is controlled by the Brownian diffusion of suspended nanoparticles in 
the airways. It is the primary mode of deposition in the alveoli due to the limited 
convection of air in the tiny pores.  This mechanism is only considered important 
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if it is found that particles deposit in the alveolus and are below a few microns in 
diameter.13,17   
 
1.1 A Brief History of Pulmonary Drug Delivery 
Pulmonary delivery stands out among the various delivery schemes for its fast 
onset of action and relative ease of administration.18 Indeed, the pulmonary route 
has been employed since ancient times for the administration of various drug 
substances, but it has only recently gained attention in the modern medical field.18 
Various steroid based aerosols used to treat asthma were developed in MDIs and 
brought to the market in the 1950s.19 After this time, developments in pulmonary 
delivery began to diminish, but DPIs were able to make their debut around 
1970.11  
DPIs were advantageous to MDIs because the patient did not have to 
coordinate his or her inspiration with the device actuation, drug was less likely to 
impact upon the patient’s throat, and no environmentally harmful propellants 
were needed.9,20 A major drawback with the performance of DPIs was that a 
portion of the inhaled particles would often get stuck in the upper airways due to 
particle agglomeration or insufficient aerosolization which caused inconsistent 
dosing.9,11 Over the next twenty years, new designs were introduced to both 
improve the usability of the devices and increase the number of doses the DPIs 
could store.11 Pulmonary delivery became increasingly attractive both to present 
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drugs locally to the lungs, as well as to deliver therapeutics through the lungs to 
the systemic environment without experiencing the effects of first pass 
metabolism.9 Along these lines, pulmonary drug delivery is now increasingly seen 
as a viable strategy for treating a number of diseases such as lung cancer, primary 
pulmonary hypertension, cystic fibrosis, chronic obstructive pulmonary disease, 
emphysema, and tuberculosis.10,21 
Pulmonary delivery vehicles may be composed of a variety of materials 
including; pure drug particles, nebulized liquid droplets, biodegradable polymers, 
etc.22 For example, aerosolized and intratracheal bolus doses of surfactants, 
synthetic and natural, have been delivered to the pulmonary bed in treatment of 
various respiratory distress syndromes.23,24 Synthetic surfactants consist primarily 
of dipalmitoylphosphatidylcholine (DPPC), while natural surfactants may be 
harvested from the bovine lung.25 These surfactants may also be used in drug 
delivery formulations.26 Experience has shown that, depending on the drug, the 
desired time of release and site of action, one delivery vehicle may be preferred 
over another.27  
While device design was explored during the infancy of pulmonary drug 
delivery, material selection has recently received much attention. Biodegradable 
polymers have had a greatly positive impact in pulmonary medicine.28 PLGA, 
poly (lactic-co-glycolic acid) is one such polymer that has been micronized for 
pulmonary delivery.29 Lai et al., showed a therapeutic effect in using this polymer 
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to intratracheally deliver isoproteranol to achieve bronchodialation in serotonin 
challenged rats.30 New studies have looked into PEG-based polymeric vesicles to 
overcome some of the limitations of PLGA based drug delivery.31 PEG is slowly 
degraded via surface erosion kinetics as compared to the hydrolytic acid catalyzed 
bulk erosion of PLGA.9,31 Chitosan is a polysaccharide, a sugar-based polymer, 
that has been employed in several pulmonary formulations to improve release 
kinetics and drug permeability.32 As time continues, all of these technologies may 
be refined and used to improve pulmonary drug delivery. 
 
1.2 Pulmonary Physiology and Molecular Transport 
The lungs are dynamic organs that serve as the core of the respiratory tract in 
all species of land animals.33 The respiratory tract contains a great number of 
different tissues and regions, each with unique structure and function. A diagram 
of these various regions is shown below.   
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Larynx
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Alveolar ducts and sacs
 
Figure 1.3 Diagram of the various structures within the human lung physiology. 
Adapted from Hillary, et al., 2001.  
 
 
Transport issues should be considered for the entire respiratory tract when 
designing a pulmonary drug delivery device. The various regions are composed of 
unique tissue structures that serve as barriers to drug delivery. If the cells on the 
surface of the airways are ciliated they may remove particles before drug can be 
dissolved to the mucosal layers. Epithelial cells equipped with a protective 
extracellular matrix and an increased number of tight junctions will prevent 
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transport of hydrophilic molecules. Hydrophobic molecules may pass through cell 
walls and into systemic circulation, but dense submucosal layers and a highly 
charged mucus layer may prevent this route of drug transport.  
Aside from these barriers, drug entities delivered via the lungs are able to 
avoid first pass metabolism in the liver and this may increase overall 
bioavailability.34 There is evidence that drugs containing an ester moiety may 
experience a pulmonary first pass effect due to enzymatic degradations via 
carboxylesterase isozyme, but this phenomenon is limited to specific drug types.35 
The respiratory system consists of three primary regions: the upper airways, the 
central airways and the peripheral airways. A more detailed depiction of some of 
the surfaces of these regions is shown in Figure 1.3. 
The upper airways share regions with the gastrointestinal tract (mouth, 
oropharynx, larynx, and trachea). The pulmonary route literally begins at the 
mouth and leads to the throat.1 These surfaces are composed of a non-keratinized 
epithelial layer with a saliva based mucus layer that interfaces with the air, and a 
mucosa layer between 0.5 and 0.8 mm in thickness.9 The oropharyngeal region 
follows, which includes the oropharynx and the larynx (nasal anatomy in this 
region is omitted for brevity). Inhaled air then passes through the trachea. An 
image of this region is shown below. 
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cilia columnar epithelium cells
basal cells
lamina propria
Figure 1.4. Histological section of the ciliated epithelial layer in the upper 
airways. Bar = 50 µm. Courtesy of KU Medical Center. 
 
Figure 1.4 shows the typical ciliated morphology of the mucosal cells which 
facilitate mucociliary transport between this region and throughout the lung 
tissues to the terminal bronchioles. Particles with an aerodynamic diameter 
greater than 10 µm may be deposited in this region due to heavy impaction. This 
has been the case in early devices, and some studies have shown anywhere from 9 
to 76% deposition in the mouth and throat for monodisperse aerosols.36 Virtually 
no drug deposited here is able to transport through the cell layers before being 
swallowed or expectorated. 
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 The next region is the central or conducting airways. This area consists of the 
lower trachea, main bronchus and the many bifurcations that make up the 
bronchiole tree (~23 in total). This region is not considered ideal for drug delivery 
as it contains a thicker, less penetrable epithelium that the distal branches and 
alveoli, and also contains cilia and a mucus layer which provide for constant 
mucociliary clearance from the walls of the bronchi, sweeping particles up to the 
trachea and down into the GI tract. An image of this region is shown below. 
 
Figure 1.5. Histological section of the walls of a bronchus. Bar = 100 µm. 
Courtesy of KU Medical Center. 
 
This region is primarily lined with ciliated and goblet cells. The goblet cells 
secrete components of the mucus layer along with the submucosal glands, and the 
ciliated cells provide for clearance. Serous, brush, and clara cells are also present 
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in small amounts. The surfactant that covers the mucus layer is provided by 
epithelial type-II cells. These are cuboidal pneumocytes which exclusively secrete 
a pulmonary surfactant consisting of a specific mixture of lipoproteins and lipids, 
the majority of which is phosphatidylcholine. The surfactant decreases surface 
tension upon exhalation and also helps reconstitute proper morphology upon 
inhalation.9   
The final region of the airways is the peripheral airways, which consists of the 
terminal bronchi and the alveoli. This region is usually considered the optimal 
location for particle deposition, because it contains the largest surface area for 
molecular transport, a minimal surfactant layer to impede transport, the thinnest 
layers of epithelium to shorten transport events, and no ciliated cells. An image of 
this region is shown below.  
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Figure 1.6. Histological section of the alveolar region in the human lung. Insert 
shows a schematic of the blood/alveolar interface. Blue arrows point to type I 
pneumocytes, green arrows point to type II pneumocytes. Bar = 30 µm. Courtesy 
of KU Medical Center. 
capillary endothelium
alveolar epithelium
fused basal lamina
type I pneumocyte
red blood cell
 
This region is composed of type I and II pneumocytes. Type I cells compose 
about 33% of the cell mass, but they compose almost 93% of the alveolar surface. 
These cells are very thin, about 0.05 µm, and offer a direct route to the systemic 
circulation for gases. Type II cells are responsible for secreting the surfactant that 
regulates surface tension on the surface of the alveolar lumen. This layer 
interfaces with the endothelium of the blood capillaries via a fused basal lamina. 
This region can be as thin as 0.5 microns wide and primarily allows for rapid gas 
exchange between the airways and the blood, but it is also a target area for drug 
transport into the systemic environment. 
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The alveolar region contains macrophages which exist primarily to engulf and 
clear harmful particulates. Particles that are taken up by macrophages may endure 
one of several fates. Most often, they are transported to the terminal bronchioles, 
where they are then cleared via mucociliary clearance. Nanoparticles may also be 
carried though the alveolar epithelium and reach the lymphatic tissues in the 
interstitium. The particles are then translocated to the bronchial associated 
lymphatic tissue where they are released back into the upper airways for clearance 
via exhalation. This is a possible fate for deposited nanoparticles, and it yields 
clearance rates comparable to the mucociliary pathway for microparticles.37 
Particles that are able to reside in the alveolar region for a period of time may 
release their drug via particle erosion, particle degradation, and/or drug 
dissolution. Dissolved drug can then transport through the cell membrane or 
between type I pneumocytes, depending on hydrophobicity, and enter directly into 
the capillaries. These regions are shown in detail in Figure 1.6. 
The pulmonary environment contains a range of fluid/fluid and fluid/solid 
interfaces in the course of drug transport.33 These various interfaces include: 
air/surfactant interface between the bronchial/alveolar lumen and the mucus layer 
that covers the walls of the lumen,38 particle/air interface between the surface of 
the drug particle and the air within the bronchial and alveolar lumen,13 and 
aqueous/epithelial interface between the mucus layer and the walls of the lung 
epithelial cells that line the airways.13,39,40 In the course of delivering drugs via the 
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pulmonary route, any of these interfaces may be of importance in considering 
efficacy of overall drug delivery.9,13,39-41 Also, upon particle deposition there is a 
boundary between the particle and the mucus layer whereby drug release may be 
a major limiting kinetic event. Nanoparticles may be able to penetrate epithelial 
cell membranes, but the highly charged mucus layer may still provide a major 
barrier to their delivery.42  
Many barriers exist when delivering drugs locally or systemically via the 
pulmonary route, and some have already been briefly mentioned. Poor deposition 
of particulates is a primary concern.9 If particles are not able to be deposited into 
the pulmonary bed, they may deposit within upper airways such as the 
oropharynx, larynx, trachea and upper bronchioles.9,41 If this is the case, it is 
likely that the drug will be cleared via the mucociliary clearance mechanism and 
be deposited into the stomach and degraded and/or delivered into the 
gastrointestinal tract.5 If the drugs are able to deposit along the terminal 
bronchioles and within the alveoli then there is an improved probability for 
dissolution and adsorption. Hydrophobic drugs are typically poorly soluble in 
lung surfactant, though the mixture is more effective in solubilizing these drugs 
than a pure aqueous environment.43 Hydrophilic drugs bear the opposite challenge. 
Even though they may readily disperse throughout the surfactant layers, they still 
may not be provided with a suitable paracellular pathway to the capillaries 
through the tight junctions of the epithelial barrier. The surface cells in this region 
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of the lungs are characterized by their lack of interstitial spacing between cells. 
Hydrophilic drugs do not transport directly through the cell layers because they do 
not interact with the fatty surfaces of cells. Delivery may be enhanced with 
mucoadhesive delivery vehicles,26 or permeability enhancers. 
 
1.3 Manufacturing Particulates for Drug Delivery 
Popular methods to produce particles for drug delivery are usually 
characterized as top-down processes, while bottom-up processes mainly refer to 
nanoparticle fabrication via molecular self-assemblies.44 Top-down processes 
include spray drying, emulsification, anti-solvent precipitation, Supercritical CO2 
precipitation, wet milling, jet milling, and grinding. Nanoparticles can also be 
produced using these processes. Rasenack et al., have reported the micronization 
of a host of anti-inflammatory drugs for pulmonary drug delivery using a 
controlled crystallization technique, and this may be considered a bottom-up 
process for micro or nanoparticle fabrication.45 
One of the most well known methods for the production of particulate drug 
delivery vehicles is the formation of microemulsions and miniemulsions, where 
microemulsions generally refer to any liquid droplets that are stabilized against 
coalescence using surfactants with a size range between 1 and 1000 µm, and 
miniemulsions specifically refer to their nanosized counterparts with a size range 
between 1 and 1000 nm.46 Miniemulsions have been shown to provide 
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‘nanoreactor’ systems for producing solid polymer nanoparticles.46 An example is 
the emulsion polymerization technique whereby monomer is dissolved in a 
solvent and this dispersed phase is subject to shear along with a continuous phase, 
a surfactant, and an osmotic pressure agent, if necessary. The resulting 
nanosuspension is then allowed to polymerize and the solid nanoparticles are 
formed accordingly. The particles can encapsulate drug or bear it on their surface, 
depending on when the drug is introduced during the polymerization and the type 
of polymer synthesis routine such as: emulsification-evaporation, diffusion, 
solvent displacement, or salting-out.47 Polymer nanoparticles, however, are used 
less often for pulmonary delivery. 
Precipitation based methods have been used extensively for the production of 
drug particles. Solvent emulsification/evaporation methods refer to the formation 
of an oil/water emulsion that precipitates a solid suspension upon evaporation of 
the water immiscible solvent.48 A similar method involves the virtually 
instantaneous precipitation of a solid suspension upon mixing of miscible solvents. 
The solid drug material is dissolved in a solvent, and it precipitates out when the 
solvent is mixed vigorously with an antisolvent.49 The event may occur in the 
presence of stabilizers, which are shown to lower interfacial tension, increase 
nucleation rate and inhibit coagulation. The main controlling parameter in 
promoting nucleation and, thus, nanoparticle formulation is the degree of solute 
supersaturation in the antisolvent phase.50 In contrast to mechanical milling 
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processes, antisolvent precipitation can offer control over morphology of the drug 
species. 51 
Supercritical CO2 has been used as a solvent in the production of particulates 
suitable for drug delivery.52,53 Several methods are employed for supercritical 
solvent processing including rapid expansion of supercritical solutions (RESS),  
gas antisolvent recrystallization (GAS), precipitation with compressed 
antisolvents (PCA), and still others with slight variations from these three.52 Each 
is slightly different in setup, but all maintain the use of supercritical CO2 to vary 
drug solubility with minor changes in pressure. RESS refers to dissolving the 
drugs in supercritical CO2 and forcing the solution through a nozzle, thereby 
subjecting the fluid to a drop in pressure and the drug precipitates out in the form 
of particulates. This is a suitable method for drug with considerable solubility in 
the supercritical solvent.54 GAS refers to expanding a drug/solvent mixture within 
a supercritical or condensed CO2 bulk phase in a batch process. The new tertiary 
system yields much lower drug solubility than the initial solvent and particles 
precipitate out in solid form. When the drug/solvent mix is introduced via 
atomization it is known as PCA. If the CO2 phase is supercritical, PCA is known 
as SAS or ASES.52 
Spray drying is the common method for producing particulates for dry powder 
aerosol formulation. This process generally consists of atomizing a solvent 
suspension of drug and carrier into a hot air stream.55,56 The atomization forms 
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nano and/or microparticulates and the solvent evaporates quickly into the air, 
forming dry powders. Spray drying can produce microparticles with geometric 
diameters ranging from microns to tens of microns, and composition can have a 
major effect on particle morphology.57 There are some drawbacks to consider. 
Droplets that form at the nozzle usually form with a highly polydisperse size 
distribution. Resulting powders are equally polydisperse, and this may lead to 
poor deposition in the target airways. The use of caustic solvents and rapid 
heating at the air/droplet interface may lead to drug degradation. Lastly, this 
process generally requires large amounts of excipients to overcome the tendency 
for particle agglomeration upon rapid drying. These materials are not desired due 
to their added cost and potentially adverse side effects in patients. 
 
1.4 Nanoparticle Formulations for Pulmonary Drug Delivery 
 Nanoparticles are rarely used on their own for pulmonary drug delivery, since 
these tiny particles fail to deposit and can be exhaled. Instead, they may exist as a 
component in a microparticulate system; either within or on the surface of a 
carrier microparticle or within a nebulized liquid droplet suspension.58 There are a 
select few cases where nanoparticles were used independently as a pulmonary 
drug formulation. Videira et al., performed rat studies on the uptake of solid lipid 
nanoparticles into the lymphatics.59 These particles were shown to have mean 
diameters ranging between 218 and 220 nm after nebulization, and they exhibited 
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uptake into the regional lymph nodes. It was surmised that the mechanism of 
delivery was through phagocytosis via the alveolar macrophages, similar to 
ordinary particulate antigens.59  
In another study, Zhang et al.,60 studied the hypoglycemic response of rats 
with insulin nanoparticles delivered intratracheally. Briefly, 100 mg of dextran 70 
was dissolved in about 9 mL of DI water and 100 µL of alpha-butylcyanoacrylate 
was added dropwise. The particle diameter was 254.7 nm with a polydispersity of 
0.064. Glucose levels significantly decreased after administration of nanoparticle 
solutions directly into the trachea. The results showed the nanoparticles to be an 
efficacious delivery vehicle. The resulting particles exhibited comparable 
bioavailability to free insulin in solution and slightly lower bioavailability when 
compared to subcutaneous administration of insulin in solution.60 
Nanoparticles may be used exclusively as a pulmonary delivery technique, but 
it may be expected that the successful application of free nanoparticles will be 
limited. Instead, there is much more research with regards to pulmonary 
administration of microparticulates. 
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1.5 Microparticle Formulations for Pulmonary Drug Delivery 
 Microparticluate drug delivery vehicles are diverse in morphology. Previously, 
PLGA nanoparticle agglomerates were produced that form microparticle sized dry 
powders suitable for pulmonary delivery.61 This approach allows for the prospect 
of delivering drug loaded polymer nanoparticles directly to the alveolar space 
while also allowing for a porous morphology. Additionally, the use of two 
separate systems of nanoparticles in the microparticle formulation allows for 
potential bifunctionality of the overall delivery system. Combinations of sizes 
may allow for controlled release and drug combinations may easily be adapted 
into the formulation. 
Initial techniques for producing microparticles as dry powders for pulmonary 
delivery involved jet-milling of the drug.62 These particles were shown to bear flat 
geometries and subsequently high adhesion forces which made them difficult to 
disperse in the pulmonary airways.63 Along with jet milling, ball milling was 
tested for powder formulation, with similarly limited success.64 These processes 
involved high energy input that often led to reduced crystallinity of the drug and 
subsequent degradation.65 
Spray drying has been shown to produce solid microparticulates suitable for 
pulmonary delivery.6,66 Huang et al., have used spray drying to produce chitosan 
microparticles encapsulating betamethasone as a model corticosteroid inhalation 
therapy.57 As early as 1994, Chawla et al., have used this method to produce 
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salbutamol sulfate drug microparticles for aerosol delivery.56 Many other 
examples of this successful approach exist, but drawbacks are present. In the 
course of atomization and evaporation, particles are lost by adsorption to the walls 
of the air container, and they may also uncontrollably agglomerate.67 
Lactose is used as a carrier particle with micronized or nanoparticulate drug 
particles adhered to its surface.9,68 In the carrier particle strategy, drug 
microparticles and much larger (20 to 100 µm) lactose carrier particles are 
manufactured separately, usually via milling and spray drying, respectively, and 
subsequently mixed in the dry state.69 Studies reveal that both lowering the size of 
the carrier particles, and improving their surface smoothness may improve 
aerosolization of the mixture.68,70 More recent studies have shown that including a 
fraction of fine lactose particles, those with mean diameters less than 10 µm, can 
minimize the influence of carrier surface smoothness and particle size on the 
overall aerosolization, and thus performance may be improved.71  
Supercritical CO2 is often used to produce nanoparticles which are then 
incorporated into a carrier system. The solvent does work to produce 
microparticles, as well. Supercritical CO2 was used in an aerosol solvent 
extraction system (ASES) to produce fluticasone proportionate microparticles for 
use in an MDI for the treatment of asthma.72 The particles exhibited comparable 
flowability to the marketed formulation.  
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Finally, some lesser known methods have been employed for producing 
pulmonary microparticulates. Kwon et al., have described a ‘seed zone’ method 
for producing micron sized insulin crystals.73 This method takes advantage of 
insulin’s variable solubility in the aqueous due to differences in pH. Briefly, the 
team dissolved insulin in low pH solutions (pH = 2.0) and subsequently increased 
the pH stepwise with additions of NaOH until they reached the ‘seed zone’ (pH = 
10.5). Upon seeding the crystallization, the team then lowered the pH to 6.0 and 
stored the resulting microparticles. The resulting inhalable formulations exhibited 
suitable sustained release and particle sizes around 3 µm. 
Concentrated efforts to produce suitable microparticles for pulmonary drug 
delivery continue to take place. Areas of exploration include novel changes to 
processing techniques, particle morphology, controlled release, and drug types. 
Microparticles are used for efficient deposition to the deep lung, but nanoparticles 
are popular for their increased dissolution kinetics primarily due to larger surface 
areas. A merging of these two morphologies would lead to potential 
improvements in particle deposition and drug dissolution. The following chapter 
investigates the controlled agglomeration of nanoparticles in colloidal suspension 
for the fabrication of pure drug porous microparticles for pulmonary delivery. A 
model drug, nifedipine, was used in the study due to its current lack of attention in 
pulmonary formulations despite its therapeutic effect in the pulmonary tissues. 
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Abstract 
Dry powder formulations are of great interest in the field of pulmonary drug 
delivery. They provide advantages to traditional suspension and nebulized droplet 
formulations such as ease of administration and simple device design. Traditional 
powder formulations attempt to aerosolize solid microparticles and entrain them 
in the lungs during inspiration. Particles of 1-5 µm in size typically facilitate lung 
deposition, however particles of this size are too large to allow for enhanced 
dissolution kinetics. If nanoparticles were effectively delivered to these regions of 
the lung, enhanced dissolution may further improve drug bioavailability and 
efficacy.   The aim of this study was to investigate the synthesis and performance 
of nanoparticle agglomerates in the formulation of micron sized particulates for 
aerosolized pulmonary drug delivery. Nanoparticles of the hypertension drug 
nifedipine were synthesized via known solvent/anti-solvent precipitation 
techniques. The resulting colloids were destabilized via ionic charge interactions 
using common salts at different solution molarities to achieve a final 
agglomerated nanoparticle size distribution suitable for pulmonary delivery of 
particulates. Agglomerated nanoparticle sizes were observed prior to 
lyophilization and powders were collected for further characterization. 
Performance of the final micron sized powders was found suitable for delivery of 
nifedipine to the deep lung and the constituent nanoparticle agglomerates revealed 
enhanced dissolution of the drug species. 
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2.1. Introduction 
 Pulmonary formulation of dry powder aerosols represents a rapidly growing 
sector in the field of drug delivery.1 With characteristically fast onset of action, 
high bioavailability and relative ease of administration, pulmonary delivery of 
drugs presents potential advantages to many traditional dosage forms.18 
Nifedipine (NIF) is one such drug that bears complicated pharmacodynamics in 
the traditional oral dosage form. Nifedipine shows limited systemic bioavailability 
via the oral route due to a combination of enzymatic effects in the stomach and 
small intestine, primarily from P450 reductase and CYP3A mediated drug 
metabolism.74 Though it is effective in easing symptoms of severe hypertension, it 
sometimes can be harmful due to aberrant dosing leading to elevated vasodilation 
and extreme hypotension.75 Nifedipine is particularly useful in treating pulmonary 
hypertension, but hypotensive side affects hinder the drug in this case.76 Given 
orally, the concentrations that are needed to achieve beneficial effects to the heart 
may cause unwanted side affects, including an increase in mortality rate for 
patients with coronary heart disease.77 For these reasons, current oral formulations 
of nifedipine bear a largely untapped therapeutic effect that could be harnessed if 
it were consistently administered at lower dosages. Pulmonary administration of 
nifedipine is one such strategy that might alleviate the aforementioned difficulties. 
 Nifedipine is a dihydropyridine and resides in a class of calcium antagonists 
known as calcium channel blockers. The structure is shown in Figure 1.1. The site 
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of action is at the calcium channels residing on the surface of all cells and it 
primarily acts upon smooth muscle cells and heart muscle cells. Nifedipine is a 
weak acid (pKa = 3.93) and is recognized for its photosensitivity and very low 
solubility in water (~10 µg/mL in water at 37 °C).78 Most drugs in the class of 
dihydropyridines bear similar physical and chemical properties to nifedipine, such 
as hydrophobicity and pyridine backbone. 
 
Figure 1.1. Chemical structure of nifedipine. 
 Evidence has shown nifedipine to be effective in the treatment of vasospastic 
angina, hypertension, aortic regurgitation, and chronic angina but not unstable 
angina.79 This drug has shown a wide range of therapeutic effect, but often it is 
abandoned due to side affects such as pronounced hypotension, diarrhea, 
hepatotoxicity, mental confusion, and even death.79,80 It has also been shown to 
cause gastritis in the GI tract.81 These side effects, however, are primarily the 
result of excess drug in the dose as is required for current oral formulation. The 
common site of action for nifedipine is at the heart or the lungs, in the case of 
primary pulmonary hypertension. If nifedipine were able to be delivered via the 
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pulmonary route then it would be present at sufficient doses in the diseased tissue 
while avoiding many of its most unwanted side affects.  
 In the present study, the design and characterization of a dry powder aerosol 
of nifedipine is reported. A pulmonary formulation is envisioned as treatment of 
hypertension, primary pulmonary hypertension and/or chronic acute angina 
pectoris. Novel formulations of nifedipine have been investigated due to its poor 
solubility and limited bioavailability.82,83 Few formulations, however, have 
employed the pulmonary route for nifedipine administration. To this end, 
nanoparticle agglomerates were synthesized via the destabilization of a 
suspension of stable charged nanoparticles (NP). Stearic acid allowed for 
stabilization of the resulting colloid, and facilitated destabilization with the 
addition of electrolytes. The resulting nanoparticle agglomerates demonstrated 
excellent aerosol properties and improved dissolution compared to micronized 
drug. 
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2.2 Materials and Methods 
2.2.1. Materials 
 Nifedipine, stearic acid, and calcium chloride were purchased from Sigma 
Chemicals Co. USA and used as received in solid form. Ethanol 95% denatured, 
acetone electronic grade, and phosphate buffered salts were purchased from 
Fisher Scientific and used as received. Spectra/Por cellulose dialysis membranes 
(MWCO = 6-8 kDa) were purchased from Fisher Scientific. DI water was used 
throughout the study as obtained from a Millipore ultrapurification unit present on 
site. 
2.2.2. Preparation of nifedipine nanoparticle suspensions  
 Nanoparticles were prepared by the rapid mixing of ethanol with dissolved 
nifedipine and stearic acid into a larger aqueous volume, known as a solvent/anti-
solvent precipitation technique. In a common experiment, 10 mg of Nifedipine 
and 1 mg of stearic acid were completely dissolved in 1 mL of ethanol and 
allowed to stir overnight. This solution was added to 29 mL of cold deionized 
water via pipette injection under probe sonication (Fisher Sonic Dismembrator, 
model 500) at 60% amplitude for 20 seconds. The resulting colloid was then 
frozen at -20 °C and lyophilized, or stored in a 4 °C refrigerator until further 
processing into nanoparticle agglomerates. At this time, 3 mL was taken from the 
solution for sizing and imaging. All solution vials and reaction vessels were kept 
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covered from any light sources, as nifedipine exhibits considerable 
photosensitivity (~10% in 24 hours) from UV and visible light spectra.84 
2.2.3 Nanoparticle characterization 
 Nanoparticle size, polydispersity, and zeta potential were all measured in 
solution directly after synthesis and prior to agglomeration by dynamic light 
scattering (Brookhaven, ZetaPALS). Zeta potential measurements were 
performed using 1 mM KCl solution. All measurements were performed in 
triplicate. Briefly, 1 mL of the solution was added to a standard cuvette and the 
remaining volume was filled with deionized water. Measurements were taken at 
90 degrees to the incident light source while assuming a viscosity and refractive 
index of pure water. After arriving at a combined size, a second cuvette was filled 
with 1 mL of the colloid solution and the remaining volume was filled with KCl. 
A known voltage was then applied to this solution and data were analyzed via 
online software to determine the zeta potential of the particles in solution. 
2.2.4 Preparation of nanoparticle agglomerates 
Nanoparticle colloids were destabilized via ionic force interactions to produce 
stable agglomerates of nanoparticles. Briefly, 30 mL of the nanoparticle suspension 
was taken from refrigeration and solid salt crystals were added to 0.1 M. Directly 
after addition, the suspensions would be subject to vigorous mixing via probe 
homogenization operating at 20,000 RPM.  Samples were left to sit at room 
temperature to allow complete agglomeration over 4 hours, and then transferred to a    
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-20 °C freezer before being lyophilized in a freeze dryer (Labconco, FreeZone 1). 
Some samples were allowed to settle for 24 hours and excess water was decanted 
prior to freeze drying. Drying continued for 36 to 48 hours to remove residual water. 
Lyophilized powder was stored in glass vials at room temperature until further 
characterization. Colloid stability was tested under a range of salt molarities and 
agglomeration behaviors were observed under all conditions. 
2.2.5 Agglomerate characterization 
 Agglomerated nanoparticles were studied in solution and as a dry powder. 
After the agglomeration event was complete, a small volume (~3 mL) of the 
solution was analyzed using a Beckman Coulter Multisizer III with a 100 µm 
aperture tube. Data were collected until the output graphs showed a stable shape 
and particle counts were above 10,000. After lyophilization, particle yield was 
determined using the following equation. 
100×=
initial
powder
M
M
Yeild        (2) 
Mpowder is the mass of solids retained after lyophilization, and Minitial is the mass of 
solids introduced into the initial ethanol solution during nanoparticle fabrication 
plus the amount of salt added for agglomeration. 
 Dry powders of the nanoparticle agglomerates were analyzed by time-of-flight 
measurement using an Aerosizer LD (Amherst Instruments) equipped with a 700 
µm aperture operating at 4 psi. For this step, 5 mg of the powder were added to 
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the aerosizer and data were collected until the output graphs showed a stable 
shape and the particle counts were above 10,000. Measurements were taken under 
medium shear and no regularization.  
 A cascade impactor was then used to collect data on powder performance (see 
appendix B). Briefly, eight filters were weighed and set onto collection plates 
which were housed within eight airtight stages arranged serially and stacked on a 
level setting. Air was then pumped through the stages at a rate of 30 liters per 
minute via a vacuum pump and about 10 mg of sample were introduced at the top 
of the impactor device. The powders were allowed to deposit amongst the stages 
for 20 seconds, after which time the air flow was stopped. Filters were then 
removed from the stages and weighed a second and final time. Cut-off particle 
aerodynamic diameters for each stage were provided by the manufacturer as 
follows: pre-separator – 10.00 µm, stage 0 – 9.00 µm, stage 1 – 5.8 µm, stage 2 – 
4.7 µm, stage 3 – 3.3 µm, stage 4 – 2.1 µm, stage 5 – 1.1 µm, stage 6 – 0.7 µm, 
stage 7 – 0.4 µm and the final stage (stage 8) is intended to collect any remaining 
particulates, though complete entrainment is nearly impossible. Mass of material 
deposited on each stage of the impactor was determined by measuring the mass 
by differences of each of the filters placed on the stages. These respective masses 
were used to calculate the respirable fraction emitted via the following equation: 
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100% ×=
∑
mtot
m
RF
cutoff
F       (3) 
Where %RF is the percent of respirable mass in the powder, F and cut-off 
designate the final and cut-off stage for the calculation, m is the mass on a given 
stage, and mtot is the sum of mass on all stages. The mass median aerodynamic 
diameter, MMAD, was obtained by a linear fit of a plot of the cumulative mass 
plotted as a function of the logarithm of the effective cut-off diameter, and 
recording the diameter at the midpoint of the curve fit. 
 Finally, the powders were characterized via two simple tests: a tap density test, 
and a test for angle of repose. The tapped and untapped (bulk) densities were 
determined by demarcating a small cuvette with known volumes, and then 
inserting a small mass of powder into the cuvette (bulk density) and tapping it 
vertically against a padded bench top 50 times (tapped density).  The mass was 
divided by the initial and final volumes. From these values the Hausner ratio 
(tapped density / bulk density) and Carr’s index (Ci) [(tapped density – bulk 
density) / tapped density X 100%] were also determined for each of the 
samples.85,86 The angle of repose for each powder was measured via the fixed 
cone height method. Briefly, a glass funnel with an internal stem diameter of 5 
mm was placed 1 cm over a glass slide. Particles were allowed to flow gently 
through the funnel until a cone was formed which reached the funnel orifice. The 
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angle of the cone to the horizontal was then recorded. This test was performed in 
triplicate for each sample.  
2.2.6 Particle Imaging 
 Nanoparticles, microparticles and pure drug crystals were imaged via a 
scanning electron microscope. The samples were deposited onto mica slides in 
solution (or as received for the crystals) and allowed to evaporate overnight. 
These samples were then coated with gold palladium under an argon atmosphere 
using a gold sputter module in a high-vacuum evaporator. Samples were then 
observed for their surface morphology using a LEO 1550 field-emission scanning 
electron microscope.  
2.2.7 Dissolution Studies 
 Dissolution of the nanoparticle agglomerates, nanoparticles, and pure drug 
were observed using a Shimadzu SPD-10A UV-Vis detector set for wavelength 
detection at 240 nm. The HPLC system consisted of a SCL-10A system controller, 
LC-10AT LC pump, SIL-10A auto injector with a sample controller, and CLASS 
VP analysis software. 45:55 (water:methanol) mixture buffered to pH = 4.5 was 
used as mobile phase. Flowrates in the column were adjusted to 2 mL/hr and all 
injections were taken at 50 µL. All studies were performed via a dialysis method 
in triplicate and sink conditions were maintained at a 30:1 volume ratio. Solutions 
were allowed to stir at 200 RPM without heating. The equivalent of 4 mg was 
introduced into dialysis bags with a molecular weight cut off of 6-8 kDa.  
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2.3 Results and Discussion 
 The properties of the nanoparticle and nanoparticle agglomerate samples are 
shown in table 2.1. Nanoparticle yields were considerably lower than agglomerate 
yields (~12% lower). This was mainly due to the tendency for nanoparticles to 
adhere to the surfaces of the collection vessels. Nanoparticles were more difficult 
then their agglomerates to transport after lyophilization, and this led to low yields. 
 It is hypothesized that the stearic acid in the formulation localizes at the 
surface of the nanoparticles arranging their carbon chains to the core of the 
particles while allowing the exposed carboxyl groups to hydrogen bond with the 
surrounding water molecules. The arrangement of stearic acid leads to higher 
negative surface charges on the nanoparticles which increased their stability in 
water and also may help form agglomerates upon addition of salt. This hypothesis 
was supported from the greatly reduced zeta potential of the stearic acid particles 
as compared with the pure drug nanoparticles (data not shown). Nifedipine is a 
characteristically non polar molecule, so any accumulation of charge on the 
surface of the nanoparticles may be attributed to the stearic acid. This reasoning is 
also aided by the observation that stearic acid is slightly amphiphilic, so it likely 
acts as a surfactant between the nifedipine and the surrounding water molecules 
after particle formation.  
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Table 2.1. Nanoparticle size, polydispersity, and zeta potential for an optimal 
formulation from an ethanol solution containing 1% w/v nifedipine and using 
stearic acid as a stabilizer in a ratio of 10:1 NIF:SA. 
Particle property Value
Effective Diameter (nm) 470 ± 40
Polydispersity 0.34 ± 0.1
Zeta Potential (mV) (24) ± 6
NP Yield (%) 75 ± 5
Mean Agglomerate Dia. (um) 11 ± 6
Agglomerate Yield (%) 91 ± 4  
 
 It was observed that a main design constraint, nanoparticle size, could not be 
easily controlled by manipulating operating conditions during the formation of the 
colloid (data shown in Appendix A, Figures A2, A3). The rate of particle 
precipitation is strongly dependent on the relative solubilities of the drug in both 
phases (water and ethanol), and this effect was observed to dominate other 
potential factors in particle formation such as mixing energy and mixing time. As 
long as there was sufficient mixing of these two solvents, which was achieved via 
ultrasonication at low to moderate amplitudes, the nucleation and growth kinetics 
led to submicron particle sizes. However, if solutions were injected with too much 
drug, particle crowding would cause uncontrolled agglomeration and eliminate 
colloidal stability. 
 In designing the formulation, it was of great importance to control the surface 
charge of the nanoparticles. This is quantified as the zeta potential, shown in the 
Table 2.1. Charged particles are able to interact across long distances via 
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electrostatic forces.87 Stearic acid was used to stabilize nifedipine nanoparticles. 
Stearic acid is found in the surfactant layer that rests above the lung epithelium in 
small amounts, is solid at room temperature, amphiphilic, and has also exhibited a 
small penetration enhancing effect for specific drug types.88,89 Solidity at room 
temperature is particularly important to ensure solid morphology of the final 
powders. Also, the amphiphilic nature ensures that the molecule may act as an 
interface between the nifedipine and water phases. 
 Table 2.2 revealed flowability characteristics for three samples: stock 
nifedipine, nanoparticles and nanoparticle agglomerates.  These data helped 
elucidate the bulk powder property differences between samples. Interesting 
points were observed, such as the large angle of repose for the nanoparticles, the 
decrease in density of the unprocessed drug with respect to the nanoparticles and 
of the nanoparticles with respect to the nanoparticle agglomerates, and the 
increasing Carr’s index between the processing steps. A large angle of repose for 
the nanoparticles was probably the result of strong adhesion forces between 
particles, and specifically between nanoparticles and larger agglomerates in the 
bulk mixture. The stock drug showed some ability to pack, and this is revealed as 
the difference between bulk and tapped densities. Carr’s flowability index 
provides a general indication of interparticulate forces.27 As the index increases, 
the differences between bulk and tapped densities increase. This equates to a 
greater degree of interparticulate forces in the sample and generally poor 
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flowability. The data showed that the nanoparticle agglomerates yielded the 
highest Carr’s index. However, these indices are not an absolute measure of the 
performance of a powder. Indeed, good flowability does not equate directly to 
enhanced aerosolization. The results indicated poor flowability for agglomerates, 
but further data revealed that the agglomerates were able to sufficiently aerosolize 
for pulmonary drug delivery. 
 
Table 2.2. Flowability parameters for three samples: stock nifedipine as received, 
nifedipine/stearic acid nanoparticles and the corresponding nanoparticle 
agglomerates. 
Sample Stock Nifedipine Nif/SA NP Nif/SA Agglomerates
Bulk Density (g/cm^3) 0.9 ± 0.2 0.10 ± 0.01 0.07  ± 0.02
Tapped Density (g/cm^3) 1.0 ± 0.3 0.12± 0.01 0.09 ± 0.01
Carr's Index 10 ± 0.8 17 ± 1.0 25 ± 2
Hausner Ratio 1.1 ± 0.01 1.2 ± 0.2 1.3 ± 0.3
Angle of Repose (deg) 50 ± 1 77 ± 2 58 ± 4  
 
 The decreasing densities were congruent with other data such as the SEM 
images in Figure 2.1.  The unprocessed drug was composed of large faceted solids 
resembling crystals greater than 100 µm. This macrostructure led to the high bulk 
density observed. The agglomerate images indicate a semi-porous structure and 
this probably led to the lower densities for the processed particles. Also, large 
arrays of agglomerates were shown to be consistently under 10 µm (Figure 2.1b). 
The monodisperse distribution indicates successfully controlled agglomeration.  
 47
ADC
B
 
Figure 2.1. A collection of SEM images for nanoparticles (A), nanoparticle 
agglomerates with 1:1 salt addition (B), close up of a single agglomerate (C), and 
pure nifedipine crystals as received (D). Scale bars are 1, 10, 10, and 100 µm, A-D. 
  
 
 To begin characterization of the final powders, particle samples were tested on 
an aerosizer and a multisizer test their aerodynamic and geometric diameters, 
respectively (Figure 2.2). The multisizer data were collected in solution, and were 
important at this stage in the synthesis to verify the agglomeration event since it is 
well known that particles can agglomerate upon lyophilization. The samples 
revealed a fairly monodisperse distribution of sizes between about 2 and 20 µm, 
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with an average diameter of about 10 µm. More so, the data revealed very stable 
microstructure in the nanoparticle agglomerates. Their distributions were barely 
altered after intense homogenization, and the curves maintain their overall shape 
(Appendix A, Figure A2). Aerosizer data revealed a more monodisperse size 
distribution and a lower mean diameter. 
 The relationship between aerodynamic diameter and geometric diameter may 
be recalled from equation (1). The variables are arranged so that if the particle 
density is lower than that for water, then the aerodynamic diameter will be some 
fraction of the geometric diameter. Also, irregularly shaped particles yield a shape 
factor greater than one which will lead to the aerodynamic diameter being some 
fraction of the geometric diameter.  In the case of our agglomerate samples, the 
geometric diameters were shown to be much larger, on average, than the 
aerodynamic diameters. For the sample shown in Figures 2.2, the average 
geometric diameter was about five times larger than the average aerodynamic 
diameter. Comparing these graphs offered a consistent confirmation that the 
particles were porous. The difference between particle distributions for the 
aerodynamic and geometric measurements suggested that the particles have 
excellent aerodynamic properties. 
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Figure 2.2. Aerodynamic and geometric diameter size distribution for a sample of 
nanoparticle agglomerates.  
 
 SEM micrographs from Figure 2.1 revealed the morphology of nanoparticles, 
nanoparticle agglomerates and pure drug. Images helped validate that 
nanoparticles agglomeration led to microparticle formation, since the images 
clearly indicated assemblages of nanoparticles. Wastewater treatment studies have 
shown that colloidal particles will agglomerate due to van der Waals forces, and 
that electrostatic forces are essential to avoiding this agglomeration.90 These 
studies provide an ample background for gaining insight into colloidal 
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destabilization. The colloids, studied here, required simple charge neutralization 
to cause this agglomeration to occur. It is not surprising that the addition of 
electrolytes in the form of sodium chloride caused nanoparticle agglomeration, 
since stearic acid formed only a weakly negative surface charge to stabilize the 
nanoparticles. The mechanism has also been shown to benefit from anion 
presence, which further justifies the use of NaCl.90 
 The nanoparticle SEM images in Figure 2.1 showed a somewhat elliptical 
morphology with an average diameter somewhere below one micron, but not as 
small as 100 nm, which was consistent with DLS data. The nanoparticle 
agglomerate images revealed a highly textured morphology, with many small and 
similarly shaped protrusions from the surface. These features were indicative of 
the mechanism behind particle formation, as they were probably the result of 
nanoparticles grouped together during the agglomeration step. Also, we can see a 
somewhat porous assembly (Figure 2.1c). In comparison, the stock drug was 
shown to bear a highly faceted structure, and particles resembling crystals larger 
than 100 µm were observed. This faceted morphology was not observed in any of 
the other images, thus suggesting a possible change in overall crystallinity.  
 DSC thermographs were used to investigate the effects of processing on drug 
morphology, and to verify the overall content in each of the formulations. Both 
stearic acid and nifedipine exhibited sharp endothermic troughs where they 
undergo a melting phenomenon upon heating (Figure 2.3). Endothermic troughs 
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at the nifedipine and stearic acid location show up in all the graphs; however, 
their extent and exact shape undergo changes. Firstly, it can be seen that the area 
between the curves and the baseline decreased for all processed samples. This is 
probably due to the increased surface area and faster heating of smaller 
particulates. Overall heating requirements were calculated using a peak 
integration method (Table 2.3). Processed samples all showed lower heating 
requirements on a per mass bases compared to the stock materials, which was 
consistent with more efficient heating of smaller particles. The data showed peak 
locations close to the original locations in the stock material, verifying the 
samples composition. The heating requirements for any of the peaks were far 
lower than those for typical ethanol evaporation (heat of vaporization = 877 J/g), 
so we may conclude that negligible solvent was present in the processed particles. 
 
Table 2.3. DSC peak integrations for stock nifedipine, stock stearic acid, NIF 
nanoparticles, NIF/SA nanoparticles and NIF/SA agglomerates. 
Sample Peak location (°C) Peak area (J/g)
Nifedipine 174 121
Stearic acid 76 245
NIF nanoparticles 150 30
156 28.8
NIF/SA nanoparticles 67 24.2
152 32
160 38.8
NIF/SA agglomerates 67 9.1
163 36.3  
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 It is worth noting the changed shape of the nifedipine peak for both 
nanoparticle samples, which revealed an exothermic peak indicative of a 
crystallization event, or some other energy yielding phenomenon (Figure 2.3). It 
may be hypothesized that the peaks result from a morphology change in the 
processed nifedipine upon heating, and this may have occurred if the nifedipine 
was in an amorphous state beforehand. The exotherm is not present in the 
agglomerated sample, so perhaps the drug already reconfigured during or after the 
agglomeration step. No other theory for this exothermic behavior has been 
surmised thus far. But, it is certainly not an interaction between the nifedipine and 
the stearic acid, since it appears for the pure nifedipine nanoparticles as well.   
 
 53
 Figure 2.3. Differential scanning calorimetry outputs for stearic acid, nifedipine, 
pure nifedipine nanoparticles, nifedipine/stearic acid nanoparticles, and 
nifedipine/stearic acid/NaCl nanoparticle agglomerates.  
 
  Dissolution studies were conducted to measure the rate of nifedipine 
dissolution from the various forms of processed drug (Figure 2.4). Drug was 
mostly dissolved from nanoparticle and nanoparticle agglomerate samples within 
10 hours. In the case of stock nifedipine, the kinetics slowed and less drug was 
dissolved throughout the experiment compared to the other samples. The 
nanoparticles released the most drug content in the allotted time. This is to be 
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expected as their smaller size allows for a greater surface area and faster 
dissolution to take place. The nanoparticle agglomerates dissolved faster than the 
stock drug by a considerable margin, but not as quickly as the nanoparticle 
suspension. The comparative dissolution rates indicated that dissolution rate 
increased for decreasing particle sizes. This behavior may also allude to improved 
dissolution characteristics of the agglomerates in the deep lung, though it was 
noted that the aqueous solutions used in the dissolution study may not sufficiently 
represent the environment within the lungs. 
 
 Figure 2.4. Percent drug dissolution versus time for the nifedipine/stearic acid 
nanoparticles, nanoparticle agglomerates, and stock nifedipine as received.  
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 Particle size was shown to affect the overall rate of particle dissolution (Figure 
2.5). Dissolution data was fit for first order kinetics, using the general first order 
rate equation shown below. 
( )
( ) Cktd
Cd ×=         (3) 
Where C is the concentration of undissolved drug, k is a rate constant and t is time. 
The equation can be solved for the single boundary condition where no drug is 
present in solution at t = 0 to yield an exponential function. This function was fit 
against all dissolution data to get rate constants for each sample. The data 
revealed that dissolution rate was inversely proportional to particle size. The rate 
was linear to the log of particle size, which is expected since the increasing size 
has an exponential effect on the available surface area for particle dissolution. 
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Figure 2.5. First order rate constants versus the logarithm of particle diameter for 
three samples: stock nifedipine, NIF/SA nanoparticles and NIF/SA agglomerates. 
 
 Nifedipine is photosensitive, and has also shown to degrade spontaneously in 
solution.91,92 Although careful precautions were taken during sample preparation 
and dissolution studies, it was possible that portions of the total nifedipine mass 
degraded over time and the degraded species did not elute from the 
chromatography column with the native species.  Alternate peaks aside from our 
characteristic peak were observed and identified as the byproducts of nifedipine 
degradation. These peaks increased in area as the studies reached their final time 
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points (data not shown); however, aberrant peaks only represented a small 
fraction of the dissolved drug at any given time point (~1-5%). They were 
included in computing the overall concentration of drug in solution. This was 
done to ensure that all dissolved drug was accounted for, and that kinetic data was 
minimally skewed due to species degradation throughout the experiment. 
Finally, cascade impaction studies were performed to formalize powder 
characterization for pharmacological formulation characterization. The cascade 
impactor is a well known instrument initially designed in the 1950’s for 
simulating aerosol performance in the human lung. The stages are set up so that 
each of them (0-8) represents deeper penetration into the lung. Particles of smaller 
sizes are not able to maintain their trajectories as the flowrate increases between 
stages. As a result, they impact upon the filter set on top of the next stage. A more 
in depth view of the device can be found in Appendix B. Data are summarized in 
Figure 2.6 and table 2.3.  
 
Table 2.3. Cascade impaction results of three samples types: stock nifedipine as 
received, nifedipine/stearic acid nanoparticles and the corresponding nanoparticle 
agglomerates. EF% is the emitted fraction percent, RF% is the respirable fraction 
percent, and MMAD is the mass median aerodynamic diameter. 
Pure NP Floc
85 ± 12 93 ± 6 91 ± 4
5.7 < 48 ± 4.1 84 ± 0.1 94 ± 1
3.3 < 2.5 ± 1.5 84 ± 0.7 84 ± 4
4.8 ± 0.6 1.8 ± 0.2 1.4 ± 0.1
Formulations
MMAD
EF%
RF%
Cascade impaction data
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The mass separation onto different stages revealed different behaviors for 
each of the samples. The pure drug mostly deposited in the earlier stages, 1-3. 
These stages represent the pharynx and primary bronchi and so it may be assumed 
that these powders would not enter the lungs whatsoever. The dried nanoparticles 
showed the bulk of their deposition between stages 5-7 and these represent the 
terminal bronchiolar and alveolar regions. A significant subpopulation of the 
nanoparticle sample deposited in stages 1-3, suggesting the present of large 
nanoparticle agglomerates as a result of the drying process. The nanoparticle 
agglomerates showed similar deposition patterns, but deposited strongly at the 
terminal bronchioles. Studies have indicated that this is an effective region for 
drug delivery.93 
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 Figure 2.6. Cascade impactor readings for nifedipine/stearic acid nanoparticles, 
nanoparticle agglomerates, and drug as received. Data is represented as a 
percentage of mass deposited on each stage number within the cascade impactor. 
 
From the data, it appeared that both the nanoparticle samples and their 
corresponding nanoparticle agglomerates were able to deposit efficiently to the 
lungs. The primary reason for this similarity, given different processing steps, is 
that the stearic acid-modified nanoparticles uncontrollably agglomerated upon 
lyophilization and hence revealed similar deposition behaviors. Also, the 
nanoparticles appeared to be depositing in the deepest regions of the impactor, but 
these particles may be quickly exhaled in a clinical setting, since deposition in the 
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alveolus often requires breath holding.14 The agglomerated particles may bear 
further advantages to the nanoparticle formulation simply because of the ability to 
harvest them directly from solution. Via a combination of particle separation and 
drying, nanoparticle agglomerates may be isolated as a dry powder at a fraction of 
the cost of nanoparticles via lyophilization. Finally, the cascade impaction data 
(table 2.3) showed the nanoparticle agglomerates outperforming both the pure 
drug and the nanoparticle powders in all fields except for fraction emitted. The 
nanoparticle agglomerates showed an exceptional respirable fraction above 5.7 
µm at 94.5% while the nanoparticles only presented 84.4% respirable at or below 
this diameter cutoff. Nanoparticles and nanoparticle agglomerates showed 
comparable mass median aerodynamic diameters, which, again, likely results 
from uncontrolled agglomeration of the nanoparticles during lyophilization. 
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2.4 Conclusions 
Stearic acid stabilized nanoparticles of nifedipine were synthesized via solvent 
precipitation in an aqueous solution. These colloids were destabilized using salt at 
specific molarities to induce particle agglomeration and subsequent 
microstructure formation. Nanoparticles and nanoparticle agglomerates revealed 
enhanced dissolution kinetics when compared to the stock drug. The nanoparticle 
agglomerate dry powders exhibited flowability characteristics and size 
distributions suitable for pulmonary drug delivery. Future work should focus on 
deducing the crystallinity of nifedipine at the various stages of processing, and 
performing in vivo studies to compare the effectiveness of the agglomerated 
powders with pure nanoparticles and stock drug as a dry powder formulation for 
pulmonary delivery. 
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A. Preliminary Investigations 
Throughout the course of preparing samples for the prepared study in chapter 
2, data were collected to help optimize the formulation and gain understanding of 
the processes at work. The dynamics of nifedipine nanoparticle and nanoparticle 
agglomerate synthesis were elucidated from these tables and figures. It is shown 
from table 3.1 that a range of nanoparticle sizes (200 to 700 nm) and surface 
charges (-20 to -35 mV) may be achieved through various processing conditions. 
All data in this table were obtained with ethanol as solvent and stearic acid as 
stabilizer. 
 
Table A1. Nanoparticle size, polydispersity, and zeta potential under various 
operating conditions. Drug/acid is the ratio of mass of drug to the mass of stearic 
acid used in solution. Ethanol and Water refer to the volumes of both phases in 
the nanoparticle processing step. Son. time is the mixing time. 
Sample Size (nm) Polydispersity Zeta (mV) Drug/acid Ethanol (ml) Water (ml) Son. time (s)
A 235 0.03 -20.9 50.0 1.5 30 90
B 260 0.01 -27.4 10.0 1.5 25 90
C 263 0.24 -30.4 0.7 5.0 50 60
D 264 0.51 n/a 6.0 5.0 50 120
E 308 0.26 -19.7 5.0 1.5 25 60
F 318 n/a -46.6 0.3 5.0 50 60
G 323 n/a -33.6 0.6 5.0 50 60
H 336 n/a -34.4 0.6 5.0 50 60
I 472 0.15 n/a 6.0 1.0 50 20
J 584 0.01 n/a 6.0 1.0 25 60
K 598 n/a n/a 6.0 0.1 25 40
L 635 0.46 n/a 6.0 5.0 10 60
M 653 0.23 n/a 6.0 0.1 50 60  
 
Nanoparticle formation does not show immediate dependence on either 
sonication amplitude or sonication time (tables A2, A3). However, it should be 
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noted that both tests were carried out while holding all solution variables constant 
(solvent/anti-solvent volumes, drug concentration in the solvent phase, drug/acid 
ratio). Further experiments may have shown stronger sonication amplitude and 
time dependencies if solutions were prepared under different concentrations. Even 
so, the final synthesis routine probably would not have changed since solution 
variables were chosen based on a number of reasons. The drug/stearic acid ratio 
was minimized to reduce dosing volumes and maintain pure drug morphology. 
The drug concentration in the solvent phase and the solvent/anti-solvent volumes 
were maximized to make the synthesis scheme cost effective. That is, lower 
concentrations would lead to high processing volumes and an increased energy 
cost. It remains for future work to compile a comprehensive report of the particle 
size and zeta potential dependencies under a comprehensive range of operating 
conditions.  
 
Table A2. Particle sizes under a range of sonication amplitudes. W/O = 29, D/A = 
1, Vtot = 30 mL, Prepared with 1% nifedipine in ethanol and stearic acid as a 
stabilizer. 
Amplitude (%) Effective Diameter (nm) Polydispersity
10 630 0.10
20 700 0.30
30 950 0.30
40 1060 0.01
50 1050 0.20
60 1300 0.01
70 690 0.35  
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Table A3. Particle sizes under a range of sonication times. W/O = 60, D/A = 10, 
Vtot = 30 mL, prepared with 1% nifedipine in ethanol. 
Time (seconds) Effective Diameter (nm) Polydispersity Zeta Potential
5 534 ± 28 0.09 (14.3) ± 0.82
10 507 ± 39 0.15 (12.4) ± 0.69
15 553 ± 16 0.16 (15.6) ± 1.2
30 507 ± 20 0.18 (17.6) ± 2.1
60 495 ± 50 0.26 (15.6) ± 0.64  
 
 Data suggested that stearic acid concentration may have a small effect on 
nanoparticle characteristics (table A4). It seems that increasing the concentration 
of the acid from 0.1 to 1 weight percent may slightly increase the size of the 
nanoparticle, as well as increasing the surface charge. Both of these outcomes 
follow intuitively. With more of the lipid present on the surface, the particles will 
be larger, and there will be a greater tendency for the carboxyl chains to be 
exposed to the environment which will increase the negative charge. The added 
material does not lead to an increased number of small particles possibly because 
stearic acid has no effect on the particle nucleation rate due to its higher water 
solubility compared to nifedipine.  
 
Table A4. Nanoparticle characteristics after preparation with a range of stearic 
acid (SA) concentrations in the solvent phase. Negative values are in parenthesis. 
Sample Effective Diameter (nm) polydispersity Zeta Potential
0.1 % SA 235 ± 8 0.03 (20.9) ± 3.0
0.5 % SA 259 ± 3 0.01 (27.38) ± 2.2
1 % SA 308 ± 8 0.25 (29.67) ± 1.2  
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Acetone was tested as a possible solvent phase during nanoparticle fabrication 
(table A5). Nifedipine is much more soluble in acetone than it is in ethanol, so it 
was possible to use far less solvent in making the particles. In these experiments, 
a tenth of the solvent (100 µL) was used in comparison to the ethanol experiments, 
but the same mass of nifedipine was prepared. Nanoparticles were successfully 
generated, and it can be seen that their sizes decreased from almost 700 nm to 430 
nm when increasing anti-solvent phase from 10 to 50 mL water.   
 
Table A5. Nanoparticle properties for suspensions created using acetone as a 
solvent phase. Sample names refer to the amount of anti-solvent phase (10,25 and 
50 mL). 
Sample Effective Diameter (nm) polydispersity
NP 10ml 671 ± 160 0.30 ± 0.1
NP 25ml 658 ± 130 0.30 ± 0.2
NP 50ml 431 ± 18 0.30 ± 0.01  
 
Similar dependencies on the relative amounts of solvent and anti-solvent 
phases were seen for ethanol based formulations (Table A6). In these experiments, 
the anti-solvent phase was kept constant (50 mL) and a solution of nifedipine and 
stearic acid in ethanol at (1% and 0.1%, respectively) was added in varying 
amounts (1, 2.5 and 5 mL) under sonication. The data showed that increasing ratio 
of solvent to anti-solvent increased the size of particles formed, and 
microparticles formed as this ratio increased. 
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Table A6. Nanoparticle properties for suspensions created using ethanol solutions 
under a range of volumes. Sample names are designated according to ethanol 
volume used (1, 2.5 and5 mL). 
Sample Effective Diameter (nm) polydispersity
NP 01ml 485 ± 9.5 0.3 ± 0.04
NP 25ml 1060 ± 290 0.3 ± 0.04
NP 50ml 2770 ± 160 0.5 ± 0.15  
 
It was noticed during experimentation that the solutions were less stable than 
their ethanol based counterparts. Acetone solutions tended to show foamy 
residues on their surface, while ethanol solutions are typically homogenous and 
translucent in appearance. Also, particle sizes for the acetone preparations 
increased over short periods of time probably due to uncontrolled agglomeration 
(data not shown). One potential reason this happens is because nifedipine is used 
in such high concentrations with acetone. Solutions were prepared near the 
solubility limits for both solvent phases (17 mg/mL NIF in ethanol, 250 mg/mL 
NIF in acetone). The higher concentrations used in the acetone solutions may 
have resulted in nanoparticles forming in closer proximity upon mixing of the 
solvent and anti-solvent leading to their increased tendency to agglomerate. 
Multisizer outputs for several different agglomeration routines were obtained 
(Figures A1 through A4). The figures showed aspects of the agglomeration for 
three different salts: NaCl, CaCl2, and MgSO4. Other salts were investigated to 
gain insight into the flexibility of the process. The three salts successfully 
agglomerated the nanoparticle suspensions, but discrepancies in these graphs 
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indicated that some salts were better than others in forming nanoparticle 
agglomerates.  
Figures A1 and A2 revealed the effects of homogenization on agglomerate 
samples. After stable agglomerates are formed it is not possible to break them into 
their constituent nanoparticles via homogenization. This is evident in Figure A1 
because the size distributions maintain mean diameters all around 5 µm following 
homogenization at various speeds. The Sample in Figure A2 undergoes a less 
drastic change in its size distribution after homogenization. This may possibly 
indicate an improved stability for the agglomerates, given that all homogenization 
regimes were essentially the same. 
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Figure A1. Particle size distributions for an agglomerate sample and portions of 
the sample after three homogenization regimes. Portions of a sample were subject 
to increasingly powerful homogenization regimes from 5, 15, and 25 kRPM for 
30 seconds, respectively. 
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Figure A2. Percent volume as a function of particle diameter for an agglomerated 
solution of NIF/SA nanoparticles in water after addition of NaCl to 0.1 M. Also 
shown is the same solution after homogenization at 25,000 RPM for 30 seconds.  
 
Agglomerate size may be somewhat controlled based on the amount of 
destabilizer that is added (Figure A3). The data reveal that  a high concentration 
of salt leads to larger, more polydisperse agglomerations, very small amounts lead 
to none, while slightly larger amounts of salt can induce agglomeration and the 
particles remain smaller and monodisperse. This provides a controlled variable 
that may prove useful for future formulations. 
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Figure A3. Particle size distributions for a sample of nanoparticle agglomerates 
under a range of NaCl molarities (0.01, 0.1, 1, and 10 Molar) marked from lowest 
to highest. Salt was added with homogenization at 15,000 RPM for 30 seconds. 
Figure 3.3 showed agglomerates using MgSO4.  
 
MgSO4 was used as a destabilizer and the results indicated poor performance 
(Figure A4). The particles showed an extremely wide size distribution which was 
not observed with any of the other destabilizers. Also, when MgSO4 was 
introduced into the solutions, it was noticed that a drastic temperature change 
occurred, and this varied with the total amount that was added (data not shown). 
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This was seen as another drawback with MgSO4, because high temperatures can 
be harsh on drug entities and cause drug degradation. 
Figure A4. Particle size distributions for a nanoparticle solution and portions of 
the solution with MgSO4 added to vary molarities (0.1, 0.25, 0.5). Salt was added 
with homogenization at 15 kRPM for 30 seconds. 
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When used as a destabilizer, CaCl2 did not reveal an exothermic reaction upon 
addition, and it was found to be a suitable destabilizer (Figure A5). However, the 
agglomerate sizes changed drastically upon application of shear force, and the 
final sizes were probably too small for the intended use. This may be the result of 
weak interactions between the divalent ions and the nanoparticles. Aside from 
NaCl, CaCl2 was shown to be the best destabilizing salt. It would be advantageous 
to continue studies with both salts in the future. Special attention should be paid 
to minimizing salt content while maintaining proper agglomeration.  
 
Figure A5. The effects of sonication and homogenization on a agglomerated 
suspension of nanoparticles. A solution of nanoparticles was allowed to 
agglomerate to completion under 0.1M CaCl2, and portions were subject to 
homogenization at 15 kRPM for 2 minutes, and sonication at 60% amplitude for 
20 seconds.  
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B. Cascade Impactor  
 The cascade impactor has been used for decades to help analyze the 
deposition of particulates in the human pulmonary airways without performing 
actual in vivo experiments. The device simulates the deposition behavior in all 
layers of the lung. A general schematic is shown in figure A5. 
 
 
Figure A5. Schematic of a typical Anderson cascade impactor. Adapted from 
Reference: Pharacotherapy, copyright 2003 Pharmacotherapy Publications 
 
 Figure A5 shows the various stages of a typical cascade impactor and also 
diagrams how air is expected to flow through the device. A vacuum pump sucks 
air continually through the stack of filters and each filter catches particles 
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depending on their size. The cutoff size ranges based on filter number are shown 
again in figure A7, along with a diagram of where those sizes will typically 
deposit in the lung. 
 
Figure A7. Schematic representation of the relationship between particle size, 
stage number and final deposition region in the pulmonary airways for an 
Anderson cascade impactor. Adapted from Reference: Operations Manual, Model 
20-800 Ambient Cascade Impactor (non-viable), Tisch Environmental, Inc. June 
1999. 
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Particle deposition in the impactor occurs via inertial impaction. Each stage has 
an inlet and an outlet. The inlet is composed of tiny orifices that get smaller as the 
stage number increases. The orifices push the air through at varying speeds. The 
stage holds a filter that the air must move around to reach the outlet. Some 
particles will not be able to stay in the air as the stream moves around the filter 
and they impact on the filter. Smaller particles with a lower momentum stay in the 
air and move on to the next filter, where they may be impacted. Higher stage 
numbers bear faster velocities and so smaller particles are able to gain enough 
momentum to impact on the stage. A diagram of the impaction event is shown in 
figure A6. 
 
 
Figure A6. Diagram of impaction event such as those that occur within a cascade 
impactor. Adapted from Reference: Finlay, 2001. The Mechanics of Inhaled 
Pharmaceuticals, an introduction. 
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